Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

NCT04448886 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Invasive Breast Cancer
Metastatic Breast Cancer
HR-Positive Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Sacituzumab Govitecan

Sponsor

Ana C Garrido-Castro, MD

Collaborators

Merck Sharp & Dohme LLC
Gilead Sciences